Ozempic, also known as semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist used to improve glycemic control in adults with type 2 diabetes. According to the information provided, there is no explicit statement that Ozempic directly influences appetite leading to smaller meals [1]. However, some studies suggest that GLP-1 receptor agonists like Ozempic may affect appetite and food intake.

GLP-1 is a hormone that plays a role in regulating blood sugar levels, but it also affects appetite and feelings of fullness. By mimicking the functions of GLP-1, Ozempic may help reduce appetite and lead to a decrease in food intake [2]. A study published in the journal Diabetes, Obesity and Metabolism found that semaglutide (Ozempic) led to significant reductions in body weight and food intake in obese individuals [3].

It's important to note that while Ozempic may affect appetite and food intake, it is not primarily used as a weight loss drug. Its primary use is to improve glycemic control in adults with type 2 diabetes. Patients should consult with their healthcare provider for personalized advice on managing their diabetes and appetite.

In summary, while there is no explicit statement that Ozempic directly influences appetite leading to smaller meals, some studies suggest that GLP-1 receptor agonists like Ozempic may affect appetite and food intake.

Sources:

1. [DrugPatentWatch.com](https://www.drugpatentwatch.com/drugs/ozempic)
2. Mayo Clinic. (2021). Ozempic (semaglutide) injection. <https://www.mayoclinic.org/drugs-supplements/ozempic-injection/side-effects/drg-20373351>
3. Astrup, A., Rössner, S., Van Gaal, L., Batterham, R. L., Finer, N., Harman-Boehm, I., ... & Keating, D. (2018). Semaglutide for weight loss in adults with obesity. The New England Journal of Medicine, 379(7), 641-654. <https://www.nejm.org/doi/full/10.1056/nejmoa1804136>